Drug-induced neuropathies

Handbook of Clinical Neurology

Volumn 115, Issue , 2013, Pages 729-742

  Manji, Hadi ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Amiodarone; Antiretroviral; Chemotherapy; Drug induced neuropathy; Linezolid; Statins; TNF antagonists

Indexed keywords

AMIODARONE; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LINEZOLID;

ANTIRETROVIRAL; ARTICLE; CHEMICALLY INDUCED DISORDER; CHEMOTHERAPY; CLASSIFICATION; DRUG-INDUCED NEUROPATHY; HUMAN; PERIPHERAL NEUROPATHY; TNF ANTAGONISTS;

AMIODARONE; ANTIRETROVIRAL; CHEMOTHERAPY; DRUG-INDUCED NEUROPATHY; LINEZOLID; STATINS; TNF ANTAGONISTS;

ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; HUMANS; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 84881537636     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-52902-2.00042-4     Document Type: Chapter

References (82)

1. Affandi J., Price P., Imran D., et al. Can we predict neuropathy before Stavudine prescription in a resource setting. AIDS Res Hum Retroviruses 2008, 24:1281-1283.
2. Albers J.W., Chaudhry V., Cavaletti G., et al. Interventions for preventing neuropathy caused by cisplatin and related compounds (review). Cochrane Database Syst Rev 2011, 2. CD005228.
3. Andre T., Boni C., Mounedji-Bondiaf L., et al. The multicentre international study of oxaliplatin/5-fluorouracil/leucovorin in the adjuvant treatment of colon cancer (MOSAIC). N Engl J Med 2004, 350:2343-2351.
4. Boyette-Davis J., Xin W., Zang H., et al. Intraepidermal nerve fibre loss corresponds to the development of Taxol-induced hyperalgesia and can be prevented with minocycline. Pain 2011, 152:308-313.
5. Briani C., Zara G., Ronidinone R., et al. Thalidomide neurotoxicity: prospective study in patients with lupus erythematosis. Neurology 2004, 62:2288-2290.
6. Broyl A., et al. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol 2010, 11:1057-1065.
7. Cavaletti G., Gilardini A., Canta A., et al. Bortezomib-induced peripheral neuropathy: a neurophysiological and pathological study in the rat. Exp Neurol 2007, 204:259-265.
8. Cavaletti G., Frigeni B., Lanzani F., et al. Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer 2010, 46:479-494.
9. Chabner B.A., Myers C.E. Clinical pharmacology of cancer chemotherapy. Principles and Practice of Oncology 1985, Vol. 1:287-328. J.B. Lippincott, Philadephia.
10. Charness M.E., Morady F., Schmeinmann M.M. Frequent neurologic toxicity associated with amiodarone therapy. Neurology 1984, 34:669-671.
11. Chauvenet A.R., et al. Vincristine-induced neuropathy as the initial presentation of Charcot-Marie-Tooth disease in acute lymphoblastic leukaemia: a Pediatric Oncology Group Study. J Pediatr Hematol Oncol 2003, 25:316-320.
12. Cherry C., Affandi J., Rosenow A., et al. Cytokine genotype suggests a role for inflammation in nucleoside analogue-associated sensory neuropathy (NRTI-SN) and predicts an individual's NRTI-SN risk. AIDS Res Hum Retroviruses 2008, 2:117-123.
13. Chin R.L., et al. Etanercept (Enbrel) therapy for chronic inflammatory demyelinating neuropathy. J Neurol Sci 2003, 210:19-21.
14. Cocito D., Bergamasco B., Tavella A., et al. Multifocal motor neuropathy during treatment with infliximab. J Peripher Nerv Syst 2005, 10:386-387.
15. CI-Perinoms Study Group CI-Perinoms: chemotherapy induced peripheral neuropathy outcome measures study. J Peripher Nerv Syst 2009, 14:69-71.
16. Cope A., et al. The role of TNF-alpha and related cytokines in the development and function of the autoreactive T-cell repertoire. Res Immunol 1997, 148:1573-1584.
17. Darley E.S., Macgowan A.P. Antibiotic treatment of Gram positive bone and joint infections. J Antimicrob Chemother 2004, 53:928-935.
18. Davis T.M.E., Yeap B.B., Davis W.A., et al. Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Freemantle Diabetes Study. Diabetologia 2008, 51:562-566.
19. DeAngelis L.M., Gnecco C., Taylor L., et al. Evolution of neuropathy and myopathy during intensive vincristine/corticosteroid chemotherapy for non-Hodgkins lymphoma. Cancer 1991, 67:2241-2246.
20. De Vriese An S., Van Coster R., Smet J., et al. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis 2006, 42:1111-1117.
21. Ellis R.J., Marquie-Beck J., Delaney P., et al. CHARTER Group. Human Immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Ann Neurol 2008, 64:566-572.
22. Frazer A.G., McQueen I.N.F., Watt A.H., et al. Peripheral neuropathy during long term high dose amiodarone therapy. J Neurol Neurosurg Psychiatry 1985, 48:576.
23. Gaist D., Jeppesen U., Andersen M., et al. Statins and risk of polyneuropathy. Neurology 2002, 58:1333-1337.
24. Gerson S.L., Kaplan S.L., Bruss, et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother 2002, 46:2723-2726.
25. Graf W.D., et al. Severe vincristine neuropathy in Charcot-Marie-Tooth disease 1A. Cancer 1996, 77:1356-1362.
26. Gregg R.W., et al. Cisplatin neuropathy: the relationship between dosage, time and platinum concentration in neurologic tissues and morohologic evidence of toxicity. J Clin Oncol 1992, 10:795-803.
27. Grunberg S.M., et al. Progressive parathesias after cessation of therapy with very high dose cisplatin. Cancer Chemother Pharmacol 1989, 26:263-268.
28. Hart A.M., Wilson A.D.H., Montovani C., et al. Acetyl-l-carnitine: a pathogenesis based treatment for HIV-associated antiretroviral toxic neuropathy. AIDS 2004, 18:1549-1560.
29. Holland J.F., Scharlan C., Gaolani S., et al. Vincristine treatment of advanced cancer; a cooperative study of 392 cases. Cancer Res 1973, 33:1258-1264.
30. Hooper D.R., Tarnopolsky M.A., Baker S.K. Lewis-Sumner syndrome associated with infliximab therapy in rheumatoid arthritis. Muscle Nerve 2008, 38:1318-1325.
31. Inada M., Sato M., Morita, et al. Associations between oxaliplatin-induced peripherl neuropathy and polymorphisms of ERCC1 and GSTP1 genes. Int J Clin Pharmacol Ther 2010, 48:729-734.
32. Jacobs J.M., Costa-Jussa F.R. The pathology of amiodarone neurotoxicity II peripheral neuropathy in man. Brain 1985, 108:753.
33. Jain K.K. Drug-induced Neurological disorders 2001, Hogrefe and Huber, Seattle. 2nd edn.
34. Kassiotis G., Kollias G. Uncoupling the proinflammatory from the immunosuppressive properties of tumour necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J Exp Med 2001, 193:427-434.
35. Kawashiri T., Egashira N., Watanabe H., et al. Prevention of oxaliplatin-induced mechanical allodynia and neurodegeneration by neurotropin in the rat model. Eur J Pain 2011, 15:344-350.
36. Keswani S.C., Pardo C.A., Cherry C.L., et al. HIV-associated sensory neuropathies. AIDS 2002, 16:2105-2117.
37. Krarup-Hansen A., et al. Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies. Brain 2007, 130:1076-1088.
38. Krishnan A.V., Goldstein D., Friedlander M., et al. Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve 2005, 32:51-60.
39. Latov N., Sherman W.H. Improvement with etanercept (Enbrel) in chronic inflammatory demyelinating polyneuropathy. Ann Neurol 2000, 48:473.
40. Lazarou J., et al. Incidence of adverse drug reactions in hospitalised patients. JAMA 1998, 278:1200-1205.
41. Lee E., Burger S., Shah J., et al. Linezolid-associated toxic optic neuropathy: a report of 2 cases. Clin Infect Dis 2003, 37:1389-1391.
42. Lehky T.J., Leonard G.D., Wilson R.H., et al. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 2004, 29:387-392.
43. Leis A.A., Stokic D.S., Olivier J. Statins and polyneuropathy: setting the record straight (editorial). Muscle Nerve 2005, 32:428-430.
44. Lo Y.L., Leoh T.H., Tan C.E. Statin therapy and small fibre neuropathy: a serial electrophysiological study. J Neurol Sci 2003, 208:105-108.
45. Lobert S., Vulevic B., Correia J.J. Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine and vinorelbine. Biochemistry 1996, 35:6806-6814.
46. Lo-Monaco M., et al. Cisplatin neuropathy: clinical course and neurophysiological findings. J Neurol 1992, 239:199-204.
47. Lozeron P., Denier C., Lacroix C., et al. Long term course of demyelinating neuropathies occurring during tumour necrosis factor-alpha-blocker therapy. Arch Neurol 2009, 66:490-497.
48. Meyer L., Patte-Mensah C., Mensah-Nyagan A. Allopregnanolone prevents and suppresses oxaliplatin evoked painful neuropathy: multiparametric assessment and direct evidence. Pain 2011, 152:170-181.
49. Miller R.W., et al. Approaches for identifying and defining environmentally associated rheumatic disorders. Arthritis Rheum 2000, 43:243-249.
50. Mollman J.E., et al. Unusual presentation of cis-platinum neuropathy. Neurology 1988, 38:488-490.
51. Mullin S., Temu A., Kalluvya S., et al. High prevalence of distal sensory polyneuropathy in antiretroviral-treated and untreated people with HIV in Tanzania. Trop Med Int Health 2011, 16:1291-1296.
52. Ng K., Kumar K., Brew B., et al. Axonal excitability in viral polyneuropathy and nucleoside neuropathy in HIV patients. J Neurol Neurosurg Psychiatry 2011, 82:978-980.
53. Pace A., Giannarelli D., Gakie E., et al. Vitamin E neuroprotection for cisplatin neuropathy: a randomised, placebo controlled trial. Neurology 2010, 74:762-766.
54. Park D.J., Zhang W., Stoehlmacher, et al. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum based chemotherapy. Clin Adv Hematol Oncol 2003, 1:162-166.
55. Park S.B., Lin Cs.-Y., Krishnan A.V., et al. Oxalipatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain 2009, 132:368-377.
56. Park S.B., Lin C.S.-Y., Krishnan A.V., et al. Early progressive and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy. Muscle Nerve 2011, 43:367-374.
57. Pettersen J.A., Jones G., Worthington C., et al. Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity. Ann Neurol 2006, 59:148-157.
58. Phillips T.J.C., Cherry C.L., Cox S., et al. Pharmacological treatment of painful HIV-associated sensory neuropathy: a systemic review and meta-analysis of randomised controlled trials. PLoS One 2010, 5:e14433.
59. Rajabally Y.A., Varakantam V., Abbott R.J. Disorder resembling Guillain-Barré syndrome on initiation of statin therapy. Muscle Nerve 2004, 30:663-666.
60. Ramos-Casals M., Brito-Zeron P., Munoz S., et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine 2007, 86:242-251.
61. Rho J.P., Sia I.G., Crum B.A., et al. Linezolid associated peripheral neuropathy. Mayo Clin Proc 2004, 79:927-930.
62. Richardson P.G., Barlogie B., Berenson J., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003, 348:2609-2617.
63. Richardson P.G., Xie W., Mitsiades C., et al. Single agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy and molecular correlations with response and neuropathy. J Clin Oncol 2009, 21:3518-3525.
64. Richette P., et al. Sensory neuropathy revealing necrotising vasculitis during infliximab therapy for rheumatoid arthritis. J Rheumatol 2004, 31:2079-2081.
65. Richez C., Blanco P., Lagueny A., et al. Neuropathy resembling CIDP in patients receiving tumour necrosis factor-alpha blockers. Neurology 2005, 64:1468-1470.
66. Sahenk Z., Brady S.T., Mendell J.R. Studies on the pathogenesis of vincristine induced neuropathy. Muscle Nerve 1987, 10:80-84.
67. Saifee T.A., et al. Bortezomib induced inflammatory neuropathy. J Peripher Nerv Syst 2010, 15:366-368.
68. Santoro L., Barbieri F., Nucciotti R., et al. Amiodarone-induced experimental acute neuropathy in rats. Muscle Nerve 1992, 15:788-795.
69. Screnci D., et al. Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs. Br J Cancer 2000, 82:966-972.
70. Sharief M.K., McLean B., Thompson E.J. Elevated serum levels of tumour necrosis factor-alpha in Guillain-Barré syndrome. Ann Neurol 1993, 33:591-596.
71. Shemesh O.A., Spira M.E. Paclitaxel induces axonal microtubule polar reconfiguration and impaired organelle transport: implications for the pathogenesis of paclitaxel-induced polyneuropathy. Acta Neuropathol (Berl) 2010, 119:235-248.
72. Shin I.-S., et al. Guillain-Barré and Miller Fisher syndromes occurring with tumour necrosis factor alpha antagonist therapy. Arthritis Rheum 2006, 54:1429-1434.
73. Simsek I., et al. Optic neuritis occurring with anti-tumour necrosis factor (alpha) therapy. Ann Rheum Dis 2007, 66:1255-1258.
74. Stubgen J.P. Tumour Necrosis Factor-alpha antagonists and neuropathy. Muscle Nerve 2008, 37:281-292.
75. Swain S.M., Arezzo J.C. Neuropathy associated with microtubule inhibitors: diagnosis, incidence and management. Clin Adv Hematol Oncol 2008, 6:455-467.
76. Thaisetthawatkul P., et al. Vasculitic neuropathy associated with minocycline use. J Clin Neuromuscul Dis 2011, 12:231-234.
77. Thomas E., Gomez H.L., Li R.K., et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatments. J Clin Oncol 2007, 25:5210-5217.
78. Toussirot E., et al. Association of rheumatoid arthritis with multiple sclerosis: a report of 14 cases and discussion of its significance. J Rheumatol 2006, 33:1027-1028.
79. Valcour V., Yeh T.-M., Bartt R., et al. Acetyl-l-carnitine and nucleoside reverse transcriptase inhibitor-associated neuropathy in HIV infection. HIV Med 2008, 10:103-110.
80. Weimer L.H., Sachdev N. Update on medication-induced peripheral neuropathy. Curr Neurol Neurosci Rep 2009, 9:69-75.
81. Windebank A.J., Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst 2009, 13:27-43.
82. Zivkovic S.A., Lacomis D. Severe sensory neuropathy associated with long term linezolid use. Neurology 2005, 64:926-927.